SVT Bax
Alternative Names: SVT-Bax; SVT-Bax (1-10)Latest Information Update: 28 Mar 2025
At a glance
- Originator Servatus Biopharmaceuticals
- Class Antipsoriatics; Antirheumatics; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Psoriasis in Australia
- 28 Mar 2025 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Australia
- 03 Feb 2021 Servatus Biopharmaceuticals has patent covering alterations for improvement of protein drugs (Servatus Biopharmaceuticals website, February 2021)